Saniona AB (publ) (SANION.ST)
SEK 6.3
(0.0%)
SEK 6.3
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.07 Million SEK | -99.54% |
| 2022 | 236.52 Million SEK | -43.34% |
| 2021 | 417.41 Million SEK | 154.03% |
| 2020 | 164.32 Million SEK | 59.46% |
| 2019 | 103.04 Million SEK | -1.86% |
| 2018 | 105 Million SEK | 40.71% |
| 2017 | 74.61 Million SEK | 7.7% |
| 2016 | 69.28 Million SEK | 74.72% |
| 2015 | 39.65 Million SEK | 40.39% |
| 2014 | 28.24 Million SEK | 92.62% |
| 2013 | 14.66 Million SEK | 64.88% |
| 2012 | 8.89 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.89 Million SEK | -87.12% |
| 2024 Q2 | 8.87 Million SEK | 688.35% |
| 2023 Q3 | 22.08 Million SEK | -9.57% |
| 2023 Q2 | 24.41 Million SEK | 10.21% |
| 2023 Q4 | 22.46 Million SEK | 1.75% |
| 2023 FY | 1.07 Million SEK | -99.54% |
| 2023 Q1 | 22.15 Million SEK | -10.91% |
| 2022 Q2 | 93.78 Million SEK | -32.19% |
| 2022 FY | 236.52 Million SEK | -43.34% |
| 2022 Q1 | 138.3 Million SEK | 9.34% |
| 2022 Q4 | 24.87 Million SEK | 221.73% |
| 2022 Q3 | -20.43 Million SEK | -121.78% |
| 2021 FY | 417.41 Million SEK | 154.03% |
| 2021 Q1 | 96.83 Million SEK | 49.42% |
| 2021 Q4 | 126.48 Million SEK | 42.17% |
| 2021 Q3 | 88.96 Million SEK | -14.74% |
| 2021 Q2 | 104.35 Million SEK | 7.77% |
| 2020 FY | 164.32 Million SEK | 59.46% |
| 2020 Q4 | 64.8 Million SEK | 52.37% |
| 2020 Q1 | 30.34 Million SEK | 11.52% |
| 2020 Q2 | 26.64 Million SEK | -12.2% |
| 2020 Q3 | 42.52 Million SEK | 59.63% |
| 2019 Q2 | 20.44 Million SEK | -31.58% |
| 2019 Q4 | 27.21 Million SEK | 6.71% |
| 2019 Q3 | 25.5 Million SEK | 24.73% |
| 2019 FY | 103.04 Million SEK | -1.86% |
| 2019 Q1 | 29.88 Million SEK | -15.94% |
| 2018 Q4 | 35.55 Million SEK | 52.16% |
| 2018 Q2 | 26.84 Million SEK | 39.5% |
| 2018 Q1 | 19.24 Million SEK | -4.5% |
| 2018 Q3 | 23.36 Million SEK | -12.95% |
| 2018 FY | 105 Million SEK | 40.71% |
| 2017 Q2 | 21.18 Million SEK | 47.71% |
| 2017 Q4 | 20.14 Million SEK | 6.37% |
| 2017 Q1 | 14.34 Million SEK | -27.58% |
| 2017 Q3 | 18.94 Million SEK | -10.61% |
| 2017 FY | 74.61 Million SEK | 7.7% |
| 2016 Q2 | 16.67 Million SEK | 1.58% |
| 2016 Q1 | 16.41 Million SEK | 141.34% |
| 2016 FY | 69.28 Million SEK | 74.72% |
| 2016 Q4 | 19.8 Million SEK | 20.78% |
| 2016 Q3 | 16.39 Million SEK | -1.63% |
| 2015 Q3 | 12.45 Million SEK | 12.4% |
| 2015 Q4 | 6.8 Million SEK | -45.4% |
| 2015 FY | 39.65 Million SEK | 40.39% |
| 2015 Q1 | 9.32 Million SEK | -0.71% |
| 2015 Q2 | 11.08 Million SEK | 18.88% |
| 2014 Q3 | 7.41 Million SEK | 19.51% |
| 2014 FY | 28.24 Million SEK | 92.62% |
| 2014 Q4 | 9.38 Million SEK | 26.54% |
| 2014 Q1 | 3.83 Million SEK | 0.0% |
| 2014 Q2 | 6.2 Million SEK | 61.81% |
| 2013 FY | 14.66 Million SEK | 64.88% |
| 2012 FY | 8.89 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 99.929% |
| Camurus AB (publ) | 1.05 Billion SEK | 99.898% |
| Mendus AB (publ) | 129.13 Million SEK | 99.166% |
| Lipum AB (publ) | 37.3 Million SEK | 97.113% |
| NextCell Pharma AB | -576.01 Thousand SEK | 286.973% |
| Simris Alg AB (publ) | 38.64 Million SEK | 97.213% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 96.198% |
| Active Biotech AB (publ) | 44.8 Million SEK | 97.596% |
| Amniotics AB (publ) | 29.07 Million SEK | 96.295% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | 92.65% |
| BioArctic AB (publ) | 89.62 Million SEK | 98.798% |
| Cantargia AB (publ) | 290.01 Million SEK | 99.629% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 95.081% |
| CombiGene AB (publ) | 44.14 Million SEK | 97.56% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 99.247% |
| Genovis AB (publ.) | 88.19 Million SEK | 98.779% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 99.064% |
| Isofol Medical AB (publ) | 7.26 Million SEK | 85.182% |
| Intervacc AB (publ) | 79.78 Million SEK | 98.65% |
| Kancera AB (publ) | 63.07 Million SEK | 98.293% |
| Karolinska Development AB (publ) | 5.51 Million SEK | 80.486% |
| LIDDS AB (publ) | 27.75 Million SEK | 96.119% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | 85.153% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 99.208% |
| OncoZenge AB (publ) | 15.9 Million SEK | 93.229% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 99.665% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 99.699% |
| Xintela AB (publ) | 57.31 Million SEK | 98.121% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 99.407% |
| Ziccum AB (publ) | 27.87 Million SEK | 96.137% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 93.433% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 99.649% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 97.474% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 93.909% |
| Corline Biomedical AB | 30.16 Million SEK | 96.43% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 98.144% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 98.705% |
| Aptahem AB (publ) | 10.01 Million SEK | 89.244% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 99.2% |
| Fluicell AB (publ) | 28.61 Million SEK | 96.237% |
| Biovica International AB (publ) | 133.72 Million SEK | 99.195% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 94.558% |
| AcouSort AB (publ) | 25.87 Million SEK | 95.838% |
| Abliva AB (publ) | 27.86 Million SEK | 96.135% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 99.443% |
| 2cureX AB (publ) | 36.51 Million SEK | 97.051% |
| I-Tech AB | 40.14 Million SEK | 97.317% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 99.875% |
| Cyxone AB (publ) | 28.21 Million SEK | 96.183% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 99.015% |
| Biosergen AB | 26.8 Million SEK | 95.983% |
| Nanologica AB (publ) | 69.88 Million SEK | 98.459% |
| SynAct Pharma AB | 224.49 Million SEK | 99.52% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 97.562% |
| BioInvent International AB (publ) | 441.4 Million SEK | 99.756% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 95.504% |
| Alzinova AB (publ) | 36.39 Million SEK | 97.041% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 99.628% |
| Pila Pharma AB (publ) | 7.85 Million SEK | 86.291% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 99.029% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | 92.673% |